LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Listă Acțiuni・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Închisă

3.31 -3.78

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.3

Maxim

3.5

Indicatori cheie
By Trading Economics
Venit	-511K -28M
Vânzări	-13M 2.6M
EPS	-0.47
Marjă de profit	-1,077.401
Angajați	141
EBITDA	-455K -29M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+341.4% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-31M 204M
Deschiderea anterioară	7.09
Închiderea anterioară	3.31

Voyager Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 iun. 2026, 23:36 UTC

Câștiguri

Correction to Oracle Reports Higher 4Q Profit Article

10 iun. 2026, 23:19 UTC

Acțiuni populare

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 iun. 2026, 23:09 UTC

Principalele dinamici ale pieței

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 iun. 2026, 23:04 UTC

Câștiguri

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 iun. 2026, 20:44 UTC

Principalele dinamici ale pieței

Caterpillar Raises Quarterly Dividend 8%

10 iun. 2026, 23:49 UTC

Achiziții, Fuziuni, Preluări

Elliott: Northern Star Should Take No Options Off The Table

10 iun. 2026, 23:48 UTC

Achiziții, Fuziuni, Preluări

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 iun. 2026, 23:48 UTC

Achiziții, Fuziuni, Preluări

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 iun. 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 iun. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 iun. 2026, 23:46 UTC

Achiziții, Fuziuni, Preluări

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 iun. 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

10 iun. 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 iun. 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 iun. 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 iun. 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 iun. 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

10 iun. 2026, 21:57 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:52 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:35 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:22 UTC

Câștiguri

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 iun. 2026, 20:50 UTC

Market Talk

Câștiguri

Tech, Media & Telecom Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 iun. 2026, 20:39 UTC

Market Talk

Câștiguri

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 iun. 2026, 20:34 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 20:33 UTC

Câștiguri

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 iun. 2026, 20:33 UTC

Market Talk

Câștiguri

Global Equities Roundup: Market Talk

10 iun. 2026, 20:33 UTC

Market Talk

Câștiguri

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparație

Modificare preț

Voyager Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

341.4% sus

Prognoză pe 12 luni

Medie 15.14 USD 341.4%

Maxim 25 USD

Minim 8 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVoyager Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Voyager Therapeutics Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.